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Purpose: Recent studies suggest that 4DCT is unable to accurately measure respiratory-induced pancreatic
tumor motion. In this work, we assessed the daily motion of pancreatic tumors treated with SBRT, and
developed adaptive strategies to predict and account for this motion.
Methods: The daily motion trajectory of pancreatic tumors during CBCT acquisition was calculated
using a model which reconstructs the instantaneous 3D position in each 2D CBCT projection image. We
developed a metric (termed Spectral Coherence, SC) based on the Fourier frequency spectrum of motion in
the SI direction, and analyzed the ability of SC to predict motion-based errors and classify patients according
to motion characteristics.
Results: The amplitude of daily motion exceeded the predictions of pre-treatment 4DCT imaging by an
average of 3.0 mm, 2.3 mm, and 3.5 mm in the AP/LR/SI directions. SC was correlated with daily motion
differences and tumor dose coverage. In a simulated adaptive protocol, target margins were adjusted based
on SC, resulting in significant increases in mean target D95, D99, and minimum dose.
Conclusions: Our Fourier-based approach differentiates between consistent and inconsistent motion char-
acteristics of respiration and correlates with daily motion deviations from pre-treatment 4DCT. The feasibil-
ity of an SC-based adaptive protocol was demonstrated, and this patient-specific respiratory information was
used to improve target dosimetry by expanding coverage in inconsistent breathers while shrinking treatment
volumes in consistent breathers.
This manuscript was submitted to Radiotherapy and Oncology
I. INTRODUCTION
During treatment for pancreatic cancer, local failure is
a major component of disease progression (30%-50%)1.
To that end, clinicians have begun to pursue intensified
radiotherapy regimens to improve patient outcomes2-7.
Stereotactic Body Radiation Therapy (SBRT)8,9 is espe-
cially appealing as a means of intensifying local therapy,
and in recent years, encouraging clinical outcomes after
SBRT for pancreas cancer have been reported from nu-
merous centers4-7,10.
SBRT relies on accurate delivery of ablative, confor-
mal doses to the target; however, dose escalation in pan-
creatic cancer is complicated by the respiratory-induced
motion of the abdomen. The pancreas undergoes signifi-
cant breathing-induced motion as a result of respiratory
activity (as high as 2-3 cm), which necessitates expansion
of the treatment margins11-13. Additionally, the pancreas
resides in close proximity to the duodenum and stomach,
which are radiosensitive organs that, if damaged, can re-
sult in significant gastrointestinal (GI) toxicity5,6. Under
these conditions, pancreatic SBRT must balance a trade-
off between ensuring coverage of the mobile tumor while
still limiting dose to nearby sensitive organs.
Compensation for respiratory motion is often ac-
complished using 4-Dimensional Computed Tomography
(4DCT)14. By acquiring a series of 3D anatomical im-
ages throughout the respiratory cycle, 4DCT allows for
the generation of a treatment volume which encompasses
a)Author to whom correspondence should be addressed:
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the entire range of motion of the tumor. 4DCT is
used extensively to account for motion in treatment of
thoracic and abdominal tumors, and generates accurate
and reproducible data concerning lung and liver tumor
motion15,16. Pancreatic tumors, on the other hand, tend
to exhibit respiratory motion with more unstable, in-
consistent qualities17,18. As a result, recent studies have
demonstrated discrepancies between pancreatic motion
predicted by 4DCT and motion observed during treat-
ment. Minn et al demonstrated that, in the majority
of patients, pancreatic tumors could be found outside
the bounds set by 4DCT over 10% of the time during
treatment12, and Ge et al found that 4DCT underesti-
mated the safety margin needed to account for superior-
inferior motion by an average of 4 mm13. This lack of
an accurate tool to measure and compensate for patient-
specific pancreatic motion further hinders the ability to
escalate dose, as additional safety margins must be added
to the target volume to account for these uncertainties.
The aim of this study was to improve pancreatic SBRT
by better understanding and accounting for motion. To
analyze the inaccuracies of 4DCT, the motion of pancre-
atic tumors was measured using a novel mathematical
method based on projection imaging. Based on this mo-
tion, we developed metrics which predict whether the mo-
tion observed during treatment will deviate from the mo-
tion observed during 4DCT imaging. Finally, we investi-
gated an adaptive treatment protocol which uses patient-
specific respiratory information to derive individualized
margins.
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2II. METHODS
A. Patients
14 patients were treated for pancreatic carcinoma be-
tween October 2012 and February 2014. Prior to treat-
ment, CT simulation was performed to acquire a 3D CT
for dose calculation and a 4-Dimensional CT (4DCT) for
respiratory motion measurement. An abdominal bellows
system was used to record the respiratory signal, and the
acquired data were sorted into 10 phases based on tem-
poral steps from maximal inspiration to another. 3D and
4DCT images were reconstructed with a slice thickness of
3 mm. In the 4DCT, the speed of table translation was
set according to the patients breathing rate, such that
each voxel in the image was under irradiation for one
full breathing cycle. Tumors were located either in the
head (n=11) or body (n=3) of the pancreas, and 30 Gy
was prescribed in 5 fractions to an internal target volume
(ITV) which encompassed the range of motion observed
on pre-treatment 4-Dimensional CT (4DCT). Addition-
ally, the ITV was expanded using patient-specific, 0-5
mm anisotropic margins to form the planning target vol-
ume (PTV). For the purpose of this study, clinical tumor
volumes (CTV) were also drawn on the 3D CT as part
of our dosimetric analysis.
To assist with localization, patients were implanted
with radiopaque fiducial markers under endoscopic ultra-
sound guidance. The cylindrical markers were approxi-
mately 5 mm long with a ¡1 mm diameter, and were
composed either of gold (10 patients) or titanium with
a carbon coating (4 patients). Markers were implanted
into the pancreatic periphery via trans-gastric insertions
though duodenum, and during simulation and treatment,
1-6 markers (median=3) were present in the tumor. Pa-
tients were simulated and treated under free-breathing,
and cone-beam CT (CBCT) was used to localize the tar-
get before treatment. In each patient, 5-7 CBCT images
were acquired over the course of treatment (median=6).
B. Tumor trajectory
Pre-treatment 4DCT images were imported into the
MIM Software system (MIM Software Inc, Cleveland,
OH) for analysis. Each image consisted of 10 respira-
tory phases; in each phase, the fiducial markers were con-
toured and the locations of the marker centroids were cal-
culated. These centroid positions were used to calculate
the motion of the fiducial markers in the 4DCT images.
Figure 1 shows the approximate location of these tumors,
and displays the motion of these tumors as observed in
4DCT images.
The daily trajectory of the tumor throughout the
CBCT acquisition was calculated using a previously de-
veloped and validated method19. This technique was
based on the work of Poulsen et al20,21 and proceeded
as follows. CBCT images are formed from multiple 2D
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FIG. 1. Projected 3D trajectories of 14 pancreatic tumors
in the coronal (left) and sagittal (right) planes, as measured
from 4DCT images. The trajectories show the movement of
the tumor centroid, are drawn in approximate relation to one
another using the common bile duct as positional reference.
projection images acquired over time; in our method,
each projection constitutes a measurement of the tumor
position. During CBCT acquisition, approximately 650
projection images were acquired over a 2 minute time-
frame. This method calculates the 3D position of the
tumor (in patient geometry) using the position of the
radiopaque fiducial markers in these projection images,
and proceeds as follows. First, the image locations of the
fiducial markers were determined automatically in each
projection using a template matching algorithm. The lo-
cation of the fiducial in the projection images confines the
marker to lie along a line connecting the x-ray source to
the point of detection in the imager. This measurement
was also corrected for the effect of gantry sag. Next, a
3D Gaussian probability distribution function was com-
puted for the daily tumor position distribution over all
650 images. This distribution was calculated through
maximum-likelihood optimization in order to best fit
the observed locations measured in the projection im-
ages. Finally, for each sampled position, the position
of the marker was calculated in the patient by finding
the most likely position along the line of detection (ac-
cording to the Gaussian PDF). Since pancreatic tumors
are highly mobile (due to respiration), this analysis was
performed independently for each phase of the breath-
ing cycle. Respiratory phases were determined using the
superior-inferior position of the fiducial markers in the
projection images, and projections were sorted using tem-
poral phase-binning. This model was implemented using
an in-house MATLAB program (The Mathworks, Natick,
MA).
By applying this model, the daily trajectory of the tu-
mor for each fraction of treatment was calculated. A
total of 81 CBCT datasets were analyzed, each contain-
ing roughly 650 projections acquired over 2 minutes. The
fiducial marker positions determined by the automated
template matching algorithm were manually reviewed
to ensure accuracy, and errors greater than two pixels
were corrected (the position was determined correctly in
roughly 95% of the projections). Using our method, each
CBCT projection constituted a measurement of the tu-
mor position in patient geometry (given by coordinates
3Timey(s)
S
IyT
um
or
yP
os
iti
on
y(m
m
)
0 20 40 60 80 100 120
-10
-5
0
5
10
ConsistentyRespiration
InconsistentyRespiration
-10
-5
0
5
10
Frequencyy(Hz)
FF
T(
cm
)
0 0.2 0.4 0.6 0.8 1
0
0.05
0.10
0.15
0.20
0.30
SC
ConsistentyRespiration
InconsistentyRespiration
0.25
N=0.075
FIG. 2. Spectral Coherence and the consistency of respiration. The top left curve shows the tumor trajectory in the SI direction
for a patient with consistent breathing, while the bottom left curve shows the trajectory of a patient with inconsistent breathing.
The Fourier Transform (FFT) of consistent motion is dominated by a single frequency, while the FFT of inconsistent motion
contains contributions from many frequencies. Spectral Coherence (right) is defined as the percentage of the motion spectrum
below a given threshold value (denoted by the dashed line). The SC is high (0.99) in the patient with consistent breathing,
and low (0.95) in the patient with inconsistent breathing.
in the anterior-posterior, left-right, and superior-inferior
directions, AP/LR/SI), otherwise known as the tumor
trajectory. The tumor position was measured roughly five
times per second, and a full dataset encompassed 30-50
respiratory cycles. Note that this is substantially more
than the 4DCT, where each voxel contains motion infor-
mation from only one respiratory cycle.
C. Respiratory consistency
Fourier spectrum analysis was used to understand and
measure the consistency of respiration between patients.
For each tumor trajectory, the Fourier transform of tu-
mor motion in the SI direction over time was calculated.
Figure 2 shows these trajectory data for a consistent and
inconsistent breather. Note that the spectrum of the con-
sistent breather is dominated by a single frequency ( 0.3
Hz, or 18 breaths per minute), whereas in the inconsistent
breather, many frequencies ultimately contribute to the
motion. We propose to use a metric, Spectral Coherence,
to describe this behavior. Given some threshold value N,
Spectral Coherence (SC) is equal to the fraction of the
spectrum with Fourier transform values below N. As SC
approaches 100%, the respiratory spectrum is dominated
by fewer and fewer frequencies. Likewise, lower values of
SC indicate multiple respiratory frequencies contribut-
ing to tumor motion. In this work, the discrete Fourier
transform was calculated from 0 to 2.565 Hz in intervals
of 0.005 Hz.
Each patient-specific trajectory exhibited at least some
degree of respiratory inconsistency, and so the specific
value of the threshold N determined what magnitude of
consistency was considered meaningful. In this study,
the value of N was used which maximized the ability of
SC to predict motion inconsistencies (i.e. maximize the
correlation coefficient between SC and trajectory errors).
To cross-validate this value, bootstrap re-sampling was
performed. In this analysis, 10,000 random datasets were
created by sampling (with replacement) from the full set
of 81 tumor trajectories.
D. Motion metrics
In clinical practice, 4DCT is often the gold standard for
understanding and accounting for motion of the tumor
during treatment. To measure the effects of motion in
our pancreatic patients, several metrics were calculated
using the difference in expected position (from 4DCT)
and actual position (using the tumor trajectory measured
during CBCT acquisition). The position of the tumor (ei-
ther in 4DCT images or daily trajectories) was calculated
as the mean position of all fiducial markers. This analy-
sis treats the tumor as a rigid volume, and assumes that
the fiducial markers do not migrate significantly between
simulation and treatment22. To test this assumption, the
differences in position between each marker were calcu-
lated in the planning CT and each CBCT. No changes
greater than 0.5 mm were observed, which excludes the
presence of any migration or deformation greater than
this distance and validates our assumptions of rigidity.
The 4DCT trajectory described the motion of the tu-
mor during ten phases of the respiratory cycle, and the
daily trajectory described the daily motion of the tu-
mor (650 samples over 2 minutes, across roughly 20-40
complete respiratory cycles). After binning the daily tra-
jectory into the same ten phases as the 4DCT, the error
in position at each point in the trajectory was given as
the absolute distance to the expected 4DCT position (for
4that phase). These values were computed relative to the
centroid of tumor motion. By taking the mean absolute
difference across the entire daily trajectory, the Mean
Trajectory Error was calculated. This metric describes
the average magnitude of the displacement between the
4DCT position and the actual position at a given moment
in time.
E. Dosimetric calculations
To evaluate the dosimetry of a given tumor motion tra-
jectory, a hypothetical clinical scenario was considered.
The clinically-drawn CTV was expanded using the ob-
served 4DCT motion to form a simulated ITV. This ITV
was then expanded by some anisotropic margin to form
a simulated PTV. The CTV (a surrogate for the gross
tumor) underwent the daily motion trajectory calculated
from the CBCT projections; for each measured position
in the trajectory, the position of the CTV relative to its
center was given by the calculated tumor position relative
to the mean position. Based on this translation, the po-
sition of each voxel in the CTV was calculated. The PTV
was stationary with respect to the mean CTV position;
in other words, as the CTV moved with respiration, the
PTV remained stationary in absolute space. To simplify
the model, and to exaggerate differences between differ-
ent trajectories and margin strategies, the dose within
the PTV was assumed to equal the prescription, with
zero dose outside the PTV. Based on the CTV location
relative to the PTV, the dose was calculated for each
voxel in the CTV.
The predictive power of Spectral Coherence was in-
vestigated by retrospectively implementing an adaptive
protocol to account for patient-specific motion inconsis-
tencies. The 4DCT-based CTV volumes were used as
target volumes. In the non-adaptive case, the ITV-to-
PTV margin was equal to 3 mm in the AP/LR direc-
tions and 5 mm in the SI direction. In the adaptive case,
margins were adjusted for each patient according to SC.
In patients with consistent breathing, the margin for all
fractions was lowered to 3 mm in the SI direction; in cases
with less consistent breathing, the margin was increased
to 7 mm in the SI direction. Specifically, margins were
expanded for patients in the lower quartile of SC, con-
tracted in the upper quartile, and remained the same in
the middle 50%. Dose-volume histograms were computed
to compare the results of the adaptive and non-adaptive
protocol. Differences in the adaptive and non-adaptive
protocols were compared using a paired T-test.
III. RESULTS
A. Inaccuracies of 4DCT
Using the projection dataset from each CBCT acqui-
sition, the daily trajectories of each tumor were recon-
4DCT Amplitude (mm)
D
ai
ly
 A
m
pl
itu
de
, 9
5%
 (m
m
)
0 5 10 15
0
5
10
15
20
AP
LR
SI
FIG. 3. Motion amplitude of pancreatic tumors in the
anterior-posterior (AP), left-right (LR), and superior-inferior
(SI) directions. 4DCT amplitudes were measured from pre-
treatment 4DCT images. Daily amplitudes are derived from
the reconstructed tumor trajectories, and are shown here as
the distance encompassing 95% of the observed motion. The
solid line has a slope of 1, and denotes where the data would
fall if the amplitudes agreed. In nearly every case, 4DCT un-
derestimated the amplitude of motion. In the SI direction,
motion on the day of treatment exceeded the value predicted
from 4DCT by an average of 3.5 mm.
structed. The daily motion amplitude (in the AP, LR,
and SI directions) was computed from these trajectories.
To exclude transient breathing excursions and/or out-
liers, the daily amplitude was computed for each dataset
as the distance encompassing 95% of the measured posi-
tions, and was averaged for each patient across all frac-
tions of treatment. Figure 3 compares this daily ampli-
tude to the predicted motion from 4DCT imaging. 4DCT
significantly underestimated the amplitude of motion (p
¡ 0.01), and the mean differences from the measured daily
amplitude were 3.0 mm (AP), 2.3 mm (LR), and 3.5 mm
(SI).
B. Consistency of Tumor Trajectories
Figure 4 shows the tumor trajectories in the SI direc-
tion for all fractions of treatment in all patients. First,
these data provide further confirmation as to the inac-
curacies of 4DCT in predicting motion of pancreatic tu-
mors. Each dot represents one measurement of the tu-
mor position, and each measurement beyond the 4DCT
margins represents a moment when the observed daily
motion exceeded the pre-treatment prediction. Figure 4
also highlights the large differences in motion between
different patients. Moreover, these data demonstrate the
consistency of motion within each individual patient; in
particular, the relative stability of the uncertainty in SI
tumor position (defined here as 1 standard deviation of
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FIG. 4. Tumor trajectories in the superior-inferior (SI) direction. Each vertical box denotes the distance encompassing 95%
of the daily motion during one fraction of treatment. Fractions are grouped by patient, and the horizontal bars denote the
amplitude of SI motion measured in the 4DCT images for that patient. In addition to highlighting the tendency of 4DCT
to underestimate pancreatic motion, these data also demonstrate the relative stability of motion in a single patient (from
day-to-day), as well as the large differences in motion between different patients. Tumor position and 4DCT amplitude are
shown relative to the mean position.
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FIG. 5. Spectral coherence is highly correlated with mean tra-
jectory error. The solid line denotes the least-squares regres-
sion between the two quantities, and the dotted lines denote
the 95% prediction interval for determining mean trajectory
error from a given spectral coherence value.
the SI trajectory). Across all datasets, the uncertainty
of a single trajectory differed from that patients average
uncertainty by 8.3% ± 7.4%.
C. Spectral Coherence
The optimum value of the threshold N (for the calcu-
lation of SC) in our dataset was 0.075 cm, equal roughly
to the 98th percentile of values in the Fourier transform
(i.e. only 2% of respiratory frequencies had amplitudes
greater than this value in the Fourier analysis). From
bootstrap resampling analysis, the standard deviation in
the optimum threshold was 0.016 cm, with a 95% con-
fidence interval of 0.029 0.086 cm. Across all trajecto-
ries, the mean SC value was 0.980 0.011 (range, 0.949
0.996). The average difference between SC from a single
fraction and that patients average SC was 0.004, whereas
the standard deviation of mean SC between patients was
0.011. In other words, the deviations in SC between pa-
tients were substantially larger than the deviations in SC
in a single patient. Note that since N is derived from the
FFT, it depends on the sampling interval (5.48 Hz in this
dataset).
Figure 5 shows the relationship between mean tra-
jectory error and spectral coherence (SC). These data
demonstrate a strong correlation between SC (a mea-
sure of respiratory consistency) and mean trajectory er-
ror (which quantifies differences between 4DCT and ob-
served daily motion). SC explains a large fraction of the
variability in mean trajectory error (R2 = 0.491), and
the 95% prediction interval for a given SC value is 2.1
6mm. In addition, it was seen that SC added predictive
value over the more straightforward approach of using
the magnitude of motion as a predictor of trajectory er-
ror. The correlation coefficient between motion magni-
tude and mean trajectory error was r=0.55 (compared
to r=0.70 for SC). Additionally, there was less than 10%
deviation in correlation between SC and mean trajectory
error across the 95% confidence interval of the threshold
N.
A strong correlation was also seen between SC and
dosimetric quantities D90 (r=0.75), D95 (r=0.77), D99
(r=0.78), and minimum dose (r=0.79). These dose met-
rics were calculated using the simplified clinical model
which incorporates the measured motion trajectories
(Sect Dosimetric Calculations).
D. Adaptive Treatment
Table 1 shows the results of the SC-based adaptive
protocol. In the adaptive scenario, ITV-to-PTV margins
were expanded for patients with in the lower quartile of
mean SC, and shrunk in trajectories in the upper quar-
tile of mean SC. D90, D95, and D99 were significantly
increased under the adaptive protocol. Also, minimum
target dose trended towards a significant increase. In
the adaptive case, the average margin was the same as
in the non-adaptive case; however, by using SC to selec-
tively add or spare margins based on the consistency of
breathing, the treatments were improved.
Non-Adaptive Adaptive p
D90 99.2±2.6 99.7±0.8 0.01
D95 98.8±3.1 99.4±1.3 0.01
D99 97.8±4.9 98.3±3.1 0.03
Minimum Dose 95.6±7.4 96.0±5.6 0.08
TABLE I. Adaptive treatment based on spectral coherence
improves dosimetry. In the non-adaptive case, CTV-to-PTV
margins were 3 mm in the LR/AP directions, and 5 mm in the
SI direction. In the adaptive case, SI margins were decreased
2 mm for the upper quartile of SC, and increased 2 mm in
the lower quartile of SC.
IV. DISCUSSION
By combining high doses per fraction with small target
volumes, SBRT can achieve large dose gradients between
a tumor and the surrounding normal tissue. However, ac-
curate and conformal dose delivery is crucial to the suc-
cess of SBRT, and motion of the tumor presents a chal-
lenge to this therapy by blurring the boundary between
these structures. In our patients, 4DCT was unable to
accurately measure and account for this motion; on av-
erage, the motion of the tumor on the day of treatment
exceeded the motion measured from 4DCT by 3.0 mm,
2.3 mm, and 3.5 mm in the AP, LR, and SI directions.
These results agree well with previously published stud-
ies on pancreatic motion12,13, and serve to further con-
firm the drawbacks of 4DCT in abdominal imaging. The
cause of these discrepancies is unknown; however, there
are several plausible explanations. 4DCT uses external
surrogates of motion (such as a chest block or bellows)
to determine respiratory phase, and this motion may not
correlate with the actual internal motion (as seen in this
study). Moreover, 4DCT images are formed from only a
handful of respiratory cycles, and if breathing in a given
patient is inconsistent from cycle to cycle then 4DCT
data would be a poor representation of the motion over a
longer time period. Respiratory coaching may limit this
effect. In addition, it is possible that some patients may
exhibit motion changes in the time interval between sim-
ulation and treatment; however, this is less likely given
the relative stability of motion observed from day-to-day
of treatment (Fig 4).
We propose the use of Spectral Coherence (SC) to bet-
ter account for patient-specific difference in pancreatic
tumor motion, a metric which describes the relative con-
tribution of different frequencies within the respiratory
cycle to the overall motion of the tumor. Patients with
consistent breathing exhibit respiratory-induced tumor
motion which is dominated by a single (coherent) fre-
quency, whereas in patients with inconsistent breathing,
many different frequencies of motion contribute signif-
icantly to the observed tumor path. Daily respiratory
inconsistencies are comprised of varying respiratory am-
plitudes, baseline shifts, and varying respiratory periods;
although SC cannot differentiate between these different
factors affecting motion inconsistencies, it distills infor-
mation regarding this inconsistency into a single param-
eter, from which a clinical judgment can be made. Our
results show that daily SC is highly correlated with de-
viations from 4DCT motion. Additionally, in a simpli-
fied clinical scenario to determine the dosimetric effect
of that motion, SC was also highly correlated with D90,
D95, D99, and minimum dose to the tumor. Our cal-
culations depend on the specific value N chosen as the
threshold for computation of SC; in our analysis it was
shown that the ability of SC to predict trajectory errors
is stable across the 95% confidence interval of the value
for N (0.075 cm) used in this study.
These results also demonstrate the clinical relevance
of SC. In a hypothetical adaptive protocol, the average
tumor dosimetry was improved by expanding and con-
tracting the PTV margins in cases with low and high
SC, respectively. The utility of this approach is twofold.
By identifying patients with consistent breathing and
shrinking the size of treatment volumes in these cases, SC
points towards cases where dose escalation may be bene-
ficial. Likewise, by identifying patients with inconsistent
breathing, it is possible to design treatment volumes that
better cover the full range of tumor motion.
It remains to be seen how best to measure SC clinically.
In this study, SC was measured from trajectories derived
7from CBCT acquisitions, and in these cases no SC infor-
mation is available until the first fraction of treatment.
However, within a single patient, it was observed that the
motion remained stable throughout all fractions of treat-
ment, and it was seen that the trajectory derived from
a single days CBCT acquisition can predict the general
characteristics of that patients future trajectories with
an error of roughly 10%. For patients receiving three
to five fractions of SBRT, this suggests that it may be
possible to adapt the course of treatment based on res-
piratory motion observed during the initial fraction. A
better workflow would be to measure SC pre-treatment,
and it is possible, in theory, to measure SC using flu-
oroscopic imaging at the time of simulation. However,
this extra pre-treatment imaging may constitute an ad-
ditional burden to the patient.
V. CONCLUSIONS
Using projection imaging, the daily motion of 14 pan-
creatic tumors undergoing SBRT was measured immedi-
ately prior to each fraction of treatment. The amplitude
of this motion exceeded the predictions of pre-treatment
4DCT imaging by an average of 3.0 mm, 2.3 mm, and
3.5 mm in the AP, LR, and SI directions. We devel-
oped a Fourier-based approach which differentiates be-
tween consistent and inconsistent motion characteristics
of respiration using a quantity termed Spectral Coher-
ence (SC). Lower values of SC were strongly associated
with larger deviations in motion from 4DCT predictions,
and SC was positively correlated with improvements in
target dosimetry. The feasibility of an SC-based adaptive
protocol was demonstrated, and this patient-specific res-
piratory information was used to improve target dosime-
try by expanding coverage in inconsistent breathers while
shrinking treatment volumes in consistent breathers.
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